tradingkey.logo
tradingkey.logo
Search

Regeneron Pharmaceuticals Inc

REGN
Add to Watchlist
819.090USD
+13.420+1.67%
Close 10-22 16:00(ET)
85.87BMarket Cap
19.29P/E TTM

Regeneron Pharmaceuticals Inc (REGN) Revenue Performance

Updated: Jun 30, 2026

By Business

Annual
Annual
Quarterly
Sanofi
EYLEA
EYLEA HD
Bayer
Libtayo
Other revenues
Libtay-ROW
Praluent
Evkeeza
Inmazeb
Other collaboration revenue
Other products - Global
Roche
ARCALYST
REGN-COV2
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sanofi
5.88B(41.02%)
4.53B(31.91%)
3.80B(28.97%)
2.86B(23.46%)
1.90B(11.84%)
1.19B(13.96%)
1.43B(18.14%)
EYLEA
2.75B(19.16%)
4.77B(33.57%)
5.72B(43.60%)
6.26B(51.46%)
5.79B(36.04%)
4.95B(58.22%)
4.64B(59.06%)
EYLEA HD
1.64B(11.41%)
1.20B(8.46%)
165.80M(1.26%)
--(--)
--(--)
--(--)
--(--)
Bayer
1.42B(9.92%)
1.50B(10.55%)
1.49B(11.34%)
1.43B(11.75%)
1.41B(8.77%)
1.19B(13.96%)
1.19B(15.12%)
Libtayo
944.70M(6.59%)
787.30M(5.54%)
538.80M(4.11%)
374.50M(3.08%)
306.30M(1.91%)
270.70M(3.19%)
175.70M(2.23%)
Other revenues
702.60M(4.90%)
515.00M(3.63%)
536.10M(4.09%)
365.10M(3.00%)
281.20M(1.75%)
557.00M(6.56%)
413.40M(5.26%)
Libtay-ROW
507.50M(3.54%)
429.50M(3.02%)
324.30M(2.47%)
73.00M(0.60%)
--(--)
--(--)
--(--)
Praluent
262.50M(1.83%)
241.70M(1.70%)
182.40M(1.39%)
130.00M(1.07%)
170.00M(1.06%)
150.90M(1.78%)
--(--)
Evkeeza
162.20M(1.13%)
125.70M(0.89%)
77.30M(0.59%)
48.60M(0.40%)
18.40M(0.11%)
--(--)
--(--)
Inmazeb
37.40M(0.26%)
76.80M(0.54%)
69.80M(0.53%)
3.00M(0.02%)
--(--)
--(--)
--(--)
Other collaboration revenue
24.80M(0.17%)
26.00M(0.18%)
5.10M(0.04%)
400.00K(--)
--(--)
--(--)
--(--)
Other products - Global
10.10M(0.07%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Roche
--(--)
1.40M(0.01%)
211.00M(1.61%)
627.30M(5.15%)
361.80M(2.25%)
--(--)
--(--)
ARCALYST
--(--)
--(--)
--(--)
--(--)
2.20M(0.01%)
13.10M(0.15%)
14.50M(0.18%)
REGN-COV2
--(--)
--(--)
--(--)
--(--)
5.83B(36.26%)
185.70M(2.19%)
--(--)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.